Search

EHA-SEHH joint membership

Save money and time by becoming a joint member of EHA and the Sociedad Española de Hematología y Hemotherapia. We've joined forces with the Sociedad Española de Hematología y Hemotherapia (SEHH) to offer a special joint membership deal.

Read more

EHA-SIE joint membership

Save money and time money by becoming a joint member of EHA and the Società Italiana di Ematologia. We've joined forces with the Società Italiana di Ematologia (SIE) to offer a special joint membership deal.

Read more

EHA-SSH joint membership

Save money and time by becoming a joint member of EHA and the Swiss Society of Hematology. We've joined forces with the Swiss Society of Hematology (SSH) to offer a special joint membership deal.

Read more

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.

Read more

A Special Coach for the Cantera 2024

A unique tutorial for young hematologists, co-sponsored by the EHA Lymphoma Group and the Fondazione Italiana Linfomi. DatesMay 14 to May 17, 2024. LocationLecce, Italy. TopicHow the utilization of cellular therapy strategies looks for lymphomas in 2024.

Read more

The European Hematology Association (EHA) announces an Invitation to Tender (ITT) for PCO services for the EHA Annual Congress

The European Hematology Association (EHA) is pleased to inform the conference and meeting community that it will release an Invitation To Tender (ITT) for the appointment of a Professional Conference Organizer (PCO) for the EHA Congress in 2023.

Read more

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.

Read more